Last reviewed · How we verify
NCT05563077
Aerobic Exercise and Resistant Hypertension
NA trial testing Moderate-intensity interval training (MIIT) in Resistant Hypertension in 72 participants. Participants enrolled and being followed up; not accepting new ones.
1 November 2025
Quick facts
| Lead sponsor | Universidad Europea de Madrid |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 72 |
| Start date | 5 October 2022 |
| Primary completion | 1 November 2025 |
| Estimated completion | 15 November 2025 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Moderate-intensity interval training (MIIT)
- Moderate-intensity continuous training (MICT)
Conditions studied
- Resistant Hypertension — all drugs for Resistant Hypertension →
Sponsor
Universidad Europea de Madrid
Who can join
Adults 30 to 80, any sex, with Resistant Hypertension. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will examine the effects of 4 months of aerobic interval training versus continuous aerobic training on ambulatory blood pressure (ABP) and novel plasma protein biomarkers in patients with resistant hypertension. A randomized controlled trial will be performed including two exercise groups and a control group: a) moderate-intensity interval training (MIIT); b) moderate-intensity continuous training (MICT); c) usual care. MIIT could represent a superior training modality that exceeds the benefits of MICT in patients with resistant hypertension.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05563077
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Resistant Hypertension
Currently open trials in the same condition.
- NCT07383220 — Effect of Electrical Stimulation and Exercise on Blood Flow in Patients With Resistant High Blood Pressure · NA · recruiting
- NCT07081243 — Symplicity China Study · recruiting
- NCT07207226 — Arterial Stiffness as a Tool to Investigate Adherence in Resistant Hypertension · NA · recruiting
- NCT06526858 — Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant · NA · recruiting
- NCT05888233 — Allopurinol Improves Heart Function in African Americans With Resistant Hypertension · Phase 2 · recruiting
Other Universidad Europea de Madrid trials
Trials by the same sponsor.
- NCT07506837 — Effects of an HABIT-ILE-Based Intervention in Children With Cerebral Palsy · NA · not yet recruiting
- NCT07470268 — Impact of Hypertrophy-oriented Resistance Training on Muscle Mass and Quality of Life in Patients With Unresectable Panc · NA · not yet recruiting
- NCT07494903 — Effects of Vibrational Therapy on Pelvic Floor Muscle Strength and Tone in Healthy Women · NA · not yet recruiting
- NCT07524010 — Multi-Omics Characterization of Percutaneous Electrolysis in Low Back Pain · Phase 1 · enrolling by invitation
- NCT07484776 — Metabolic Flexibility in Patients With Early Triple-negative Breast Cancer · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05563077 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universidad Europea de Madrid
- Last refreshed: 18 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05563077.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing